Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients

Author(s):  
Mark H. O'Hara ◽  
Eileen M. O'Reilly ◽  
Mick Rosemarie ◽  
Gauri Varadhachary ◽  
Zev A. Wainberg ◽  
...  
2018 ◽  
Vol 21 (7) ◽  
pp. 954-959
Author(s):  
M. J. Fernández Aceñero ◽  
J. Martínez-Useros ◽  
L. Díez-Valladares ◽  
S. García-Botella ◽  
L. Ortega Medina ◽  
...  

2017 ◽  
Vol 16 (4) ◽  
pp. 26-31 ◽  
Author(s):  
Yu. Yu. Rakina ◽  
M. V. Zavyalova ◽  
N. V. Krakhmal ◽  
A. P. Koshel ◽  
S. G. Afanasyev ◽  
...  

2018 ◽  
Vol 42 (4) ◽  
pp. 47-52
Author(s):  
Y. Y. Rakina ◽  
M. V. Zav’yalova ◽  
N. V. Krakhmal ◽  
A. P. Koshel ◽  
S. G. Afanasyev ◽  
...  

In recent years, especially in developed countries, there has been an increase in the incidence of pancreatic cancer. Only 20% of tumors at the time of diagnosis are evaluated as resectable, but in these cases, the prognosis of the disease is unfavorable. The overall 5-year survival rate does not exceed 5%. Pancreatic cancer was described in the 1760s by Giovanni Battista Morgagni in his classic book “De Sedibus et Causis Morborum per Anatomen Indigatis”. Over the next 200 years, pathologists significantly improved our understanding of the macro- and microscopic features of this disease. At the same time, morphological research remained the basis of diagnostics for centuries. The introduction of immunohistochemical studies into clinical practice in the late 1970s and early 1980s radically changed our approach to diagnosing this disease. Evaluation of morphological features, as well as features of expression of markers that determine the invasive potential of such neoplasms, can serve in the future as a fundamental basis in solving questions concerning possible factors of prognosis upon malignant tumors of such a localization. Aim of research — to study the morphological and immunohistochemical features of ductal pancreatic adenocarcinoma. Materials and methods. The study included 84 patients with pancreatic cancer T1-4N0-2M0-1 stage, aged from 37 to 83, who underwent surgical treatment. Morphological study of the operating material was carried out. The condition for inclusion in the study was a histotype of the tumor, namely ductal pancreatic adenocarcinoma. Posting of the material, preparation of histological preparations, coloring, immunohistochemical examination were carried out according to a standard procedure. Results and conclusion. The study made it possible to characterize the tumor morphology, as well as the features of expression of markers associated with more evident invasive characteristics of the tumor. The results of this work may be of interest in terms of their further comparison with the parameters of various forms of progression upon pancreatic cancer.


2010 ◽  
Vol 28 (22) ◽  
pp. 3605-3610 ◽  
Author(s):  
Philip A. Philip ◽  
Jacqueline Benedetti ◽  
Christopher L. Corless ◽  
Ralph Wong ◽  
Eileen M. O'Reilly ◽  
...  

Purpose Patients with advanced pancreas cancer present with disease that is poorly responsive to conventional therapies. Preclinical and early clinical evidence has supported targeting the epidermal growth factor receptor (EGFR) signaling pathway in patients with pancreas cancer. This trial was conducted to evaluate the contribution of an EGFR-targeted agent to standard gemcitabine therapy. Cetuximab is a monoclonal antibody against the ligand-binding domain of the receptor. Patients and Methods Patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma were randomly assigned to receive gemcitabine alone or gemcitabine plus cetuximab. The primary end point was overall survival. Secondary end points included progression-free survival, time to treatment failure, objective response, and toxicity. Results A total of 745 eligible patients were accrued. No significant difference was seen between the two arms of the study with respect to the median survival time (6.3 months for the gemcitabine plus cetuximab arm v 5.9 months for the gemcitabine alone arm; hazard ratio = 1.06; 95% CI, 0.91 to 1.23; P = .23, one-sided). Objective responses and progression-free survival were similar in both arms of the study. Although time to treatment failure was longer in patients on gemcitabine plus cetuximab (P = .006), the difference in length of treatment was only 2 weeks longer in the combination arm. Among patients who were studied for tumoral EGFR expression, 90% were positive, with no treatment benefit detected in this patient subset. Conclusion In patients with advanced pancreas cancer, the anti-EGFR monoclonal antibody cetuximab did not improve the outcome compared with patients treated with gemcitabine alone. Alternate targets other than EGFR should be evaluated for new drug development.


Pancreatology ◽  
2012 ◽  
Vol 12 (1) ◽  
pp. 16-22 ◽  
Author(s):  
A.M. Luebke ◽  
M. Baudis ◽  
H. Matthaei ◽  
Y.K. Vashist ◽  
P.E. Verde ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document